Drug Profile
Research programme: infectious disease vaccines - Lumos Pharma
Alternative Names: Alpha-Gal influenza virus vaccines; Influenza virus vaccine - Lumos Pharma; Zika virus vaccine - Lumos PharmaLatest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator NewLink Genetics Corporation
- Developer Lumos Pharma
- Class Influenza virus vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections; Zika virus infection
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Zika-virus-infection in USA (Parenteral)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (Parenteral)
- 02 Feb 2016 Early research in Zika virus infection in USA (Parenteral)